The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

被引:451
作者
Burslem, George M. [1 ]
Smith, Blake E. [1 ]
Lai, Ashton C. [1 ]
Jaime-Figueroa, Saul [1 ]
McQuaid, Daniel C. [1 ]
Bondeson, Daniel P. [1 ]
Toure, Momar [1 ]
Dong, Hanqing [2 ]
Qian, Yimin [2 ]
Wang, Jing [2 ]
Crew, Andrew P. [2 ]
Hines, John [1 ]
Crews, Craig M. [1 ,3 ,4 ]
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, 219 Prospect St, New Haven, CT 06520 USA
[2] Arvinas LLC, 5 Sci Pk, New Haven, CT USA
[3] Yale Univ, Dept Chem, New Haven, CT 06520 USA
[4] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA
关键词
GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR; BREAST-CANCER; C-MET; TYROSINE KINASES; LUNG-CANCER; HSP90; UBIQUITINATION; RESISTANCE; TIVANTINIB;
D O I
10.1016/j.chembiol.2017.09.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degradation. The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degradation over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degradation leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors. Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degradation using the PROTAC technology and outline the advantages of this degradation-based approach.
引用
收藏
页码:67 / +
页数:14
相关论文
共 64 条
  • [31] Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
    Lebraud, Honorine
    Wright, David J.
    Johnson, Christopher N.
    Heightman, Tom D.
    [J]. ACS CENTRAL SCIENCE, 2016, 2 (12) : 927 - 934
  • [32] Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
    Lu, Jing
    Qian, Yimin
    Altieri, Martha
    Dong, Hanqing
    Wang, Jing
    Raina, Kanak
    Hines, John
    Winkler, James D.
    Crew, Andrew P.
    Coleman, Kevin
    Crews, Craig M.
    [J]. CHEMISTRY & BIOLOGY, 2015, 22 (06): : 755 - 763
  • [33] Targeting HSP90 for cancer therapy
    Mahalingam, D.
    Swords, R.
    Carew, J. S.
    Nawrocki, S. T.
    Bhalla, K.
    Giles, F. J.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (10) : 1523 - 1529
  • [34] The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models
    Miyajima, Naoto
    Tsutsumi, Shinji
    Sourbier, Carole
    Beebe, Kristin
    Mollapour, Mehdi
    Rivas, Candy
    Yoshida, Soichiro
    Trepel, Jane B.
    Huang, Ying
    Tatokoro, Manabu
    Shinohara, Nobuo
    Nonomura, Katsuya
    Neckers, Len
    [J]. CANCER RESEARCH, 2013, 73 (23) : 7022 - 7033
  • [35] CHEMICAL BIOLOGY Greasy tags for protein removal
    Neklesa, Taavi K.
    Crews, Craig M.
    [J]. NATURE, 2012, 487 (7407) : 308 - 309
  • [36] Neklesa TK, 2011, NAT CHEM BIOL, V7, P538, DOI [10.1038/nchembio.597, 10.1038/NCHEMBIO.597]
  • [37] Organ Shawna Leslie, 2011, Ther Adv Med Oncol, V3, pS7, DOI 10.1177/1758834011422556
  • [38] Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β1-integrins
    Pellinen, Teijo
    Arjonen, Antti
    Vuoriluoto, Karoliina
    Kallio, Katja
    Fransen, Jack A. M.
    Ivaska, Johanna
    [J]. JOURNAL OF CELL BIOLOGY, 2006, 173 (05) : 767 - 780
  • [39] Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
    Perez-Torres, Marianela
    Guix, Marta
    Gonzalez, Adriana
    Arteaga, Carlos L.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (52) : 40183 - 40192
  • [40] Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
    Peschard, P
    Fournier, TM
    Lamorte, L
    Naujokas, MA
    Band, H
    Langdon, WY
    Park, M
    [J]. MOLECULAR CELL, 2001, 8 (05) : 995 - 1004